Teva CFS Book English

Health Made in Kfar Saba was completed. In 1976, Ikapharm was in turmoil due to the change of ownership from Tiush to the Koor conglomerate, which wanted to penetrate the pharmaceutical industry. Cutting the ribbon - the most modern pharmaceutical plant in the Middle East Construction came to an end and the new building - which was designed by a German company and built by a French company - was the most advanced plant of its kind, with separate dust absorption and air handling areas. In 1977, Ikapharm moved from the old plant in Ramat Gan to the newest and most modern pharmaceutical plant in the Middle East. The entrance to the plant was decorated with tulips that were given as a gift from Holland (in the photo on the top). Thanks to extensive work to establish a quality infrastructure - including implementing GMP procedures, Quality Control (QC), and Quality Assurance (QA) - the plant managed to obtain FDA - approvals for three-four drugs by 1980. This achievement, along with the impressive building, made it particularly appealing to Teva. 1980 - Teva buys an entrance ticket to the American market It’s no wonder then that in 1980, Teva acquired Ikapharm, including the production plant in Kfar Saba, as well as Plantex. Now the company owned production facilities that were FDA approved, which enabled Teva to separate between manufacture of penicillin based drugs and penicillin- free drugs, a necessary requirement for the international health authorities. These acquisitions paved Teva’s way to the American market. In 1982, the company received FDA approval for its Kfar Saba plant and opened a company to market in the United States. The company concurrently started to be traded on the American NASDAQ Stock Market. Over the course of the 1980s, Teva became the largest and most successful drug company in Israel, and one of the flagships of Israeli industry in general. Made in Kfar Saba for the rest of the world   In the 90s, Teva continued to grow and play a central role in the global generic drug market, thanks to adopting a strategy of mergers and acquisitions in North America and Europe. The plant in Kfar Saba continued to excel: The OSD Plant started launching generic products at a faster pace and at a higher quality and over the course of the decade it started to reap the rewards of a joint R&D process with Israeli scientists from the Weizmann Institute of Science. In 1996, the drug Copaxone was launched in Kfar Saba, the first innovative drug that was developed in Israel, designed to treat Multiple Sclerosis, and a sterile plant with state of the art capabilities was built for Copaxone production, next to the OSD Plant. The 21st century - looking forward In the first decade of the 21st century, Teva grew and established its position as a leading pharmaceutical company, a status that the plant in Kfar Saba was instrumental in securing. Teva is currently the leading generic drug company in the world and one of the top 10 leading drug companies in the world . The company has a presence in 60 countries and a product range of 1,000 molecules products sold in more than 120 markets. Teva currently employs 43,000 people . In 2015, company sales amounted to 19.7 billion dollars. Even now, as a global company, the Kfar Saba site continues to be a significant point on the company map. Thanks to its fruitful launch history and professional and high quality personnel, the plant was selected by the company management to be a global leader in manufacturing biological products. 7